A SYSTEMATIC LITERATURE REVIEW OF ECONOMIC EVALUATIONS AND HEALTH UTILITY VALUES IN MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA
Author(s)
Ankita Sood, PharmD, Gagandeep Kaur, M.Pharm, Barinder Singh, RPh.
Pharmacoevidence, Mohali, India.
Pharmacoevidence, Mohali, India.
OBJECTIVES: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules and abscesses, leading to reduced mobility and impaired quality of life particularly in moderate‑to‑severe cases. This systematic literature review aims to summarize evidence regarding economic evaluations (EEs) and health utility values (HUVs) in moderate‑to‑severe HS.
METHODS: EMBASE® and MEDLINE® were searched from database inception to June 2026 using relevant keywords. Each publication was reviewed by two independent reviewers with conflicts resolved by a third reviewer.
RESULTS: Of 565 citations screened, 11 studies were included (HUV=6; EEs=5). EQ-5D was the most utilized HUV scale (n=4), followed by composite time trade-off and health utility index mark 3 (n=1 each). Baseline mean EQ-5D HUVs ranged from 0.50-0.78, declining with disease severity; Hurley stage III patients reported utilities of 0.35-0.73 versus 0.80-0.83 in stage I. Further, adalimumab significantly improved HUVs versus placebo (p<0.001). Most EEs employed cost-effectiveness and budget-impact analyses (n=2 each), followed by one cost-consequence analysis. Bimekizumab and secukinumab (n=2 each) were the most commonly assessed treatments; adalimumab was primary comparator across most studies (n=4). Secukinumab was cost-effective versus standard of care in Portugal (ICER: €9,463/QALY) and cost-saving versus adalimumab in Spain (€16,858 vs. €19,701 per responder). The introduction of bimekizumab was projected to generate a manageable incremental budget impact in France (€1.1-1.8 million/year over 5 years) and Greece (average €1.57 million/year). Key ICER drivers were treatment discontinuation rates, health-state utility values, resource utilisation patterns, time horizon; budget impact drivers were drug unit costs and adult population size.
CONCLUSIONS: HS notably impairs quality of life, especially in patients with greater disease severity. The available evidence on moderate to severe population is limited by heterogeneity in model structures, assumptions, and short‑term data, highlighting the need for more robust, long‑term real‑world economic evidence. Future research should focus on standardized modelling approaches and broader cost perspectives.
METHODS: EMBASE® and MEDLINE® were searched from database inception to June 2026 using relevant keywords. Each publication was reviewed by two independent reviewers with conflicts resolved by a third reviewer.
RESULTS: Of 565 citations screened, 11 studies were included (HUV=6; EEs=5). EQ-5D was the most utilized HUV scale (n=4), followed by composite time trade-off and health utility index mark 3 (n=1 each). Baseline mean EQ-5D HUVs ranged from 0.50-0.78, declining with disease severity; Hurley stage III patients reported utilities of 0.35-0.73 versus 0.80-0.83 in stage I. Further, adalimumab significantly improved HUVs versus placebo (p<0.001). Most EEs employed cost-effectiveness and budget-impact analyses (n=2 each), followed by one cost-consequence analysis. Bimekizumab and secukinumab (n=2 each) were the most commonly assessed treatments; adalimumab was primary comparator across most studies (n=4). Secukinumab was cost-effective versus standard of care in Portugal (ICER: €9,463/QALY) and cost-saving versus adalimumab in Spain (€16,858 vs. €19,701 per responder). The introduction of bimekizumab was projected to generate a manageable incremental budget impact in France (€1.1-1.8 million/year over 5 years) and Greece (average €1.57 million/year). Key ICER drivers were treatment discontinuation rates, health-state utility values, resource utilisation patterns, time horizon; budget impact drivers were drug unit costs and adult population size.
CONCLUSIONS: HS notably impairs quality of life, especially in patients with greater disease severity. The available evidence on moderate to severe population is limited by heterogeneity in model structures, assumptions, and short‑term data, highlighting the need for more robust, long‑term real‑world economic evidence. Future research should focus on standardized modelling approaches and broader cost perspectives.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE119
Topic
Economic Evaluation, Patient-Centered Research, Study Approaches
Topic Subcategory
Budget Impact Analysis
Disease
Rare & Orphan Diseases, Sensory System Disorders (Ear, Eye, Dental, Skin)